CVR 29312206Private limited company (ApS)Forskning og eksperimentel udvikling inden for naturvidenskab og teknik (721000)HørsholmFounded 23 Jan 2006
Compiled by Dandex from the Danish Business Registry (CVR, datacvr.virk.dk), Erhvervsstyrelsen, and annual reports filed in XBRL. Values marked Dandex estimate are computed by Dandex from that data, not registered.
Dandex is Danish Company Data. Connect it once and ask about ZADEC ApS, or any Danish company, from your assistant, the API or the command line. Answers come from the current record: owners and the ownership network, financials year by year, and the latest registered changes.
Set up DandexGross profit
-116K
DKK, annual report 2025
Result
-377.2K
DKK, annual report 2025
Equity
-2.7M
DKK, annual report 2025
MC2 Therapeutics A/SCVR 29526346, 90% to under 100% of capital and votes
FEY HOLDING ApSCVR 29530777, 5% to under 10% of capital and votes
Trine Ahlgreensince 27 May 2025
Owners of 5% or more. CVR registers shares in bands, not exact figures.
CVR 2952634690% to under 100% of capital and votessince 1 Jan 2011
CVR 295307775% to under 10% of capital and votessince 1 Jan 2011
Decided by Dandex from CVR and the filed annual reports, not registered by the company.
Fixed rules decide most of these. The auditor's report, the business model, the revenue model and the activity in its own words are read by a calibrated decision model from the report's text and the purpose clause. Each label links to its definition.
CVR records founders at incorporation. It does not record whether they are alive or still involved.
Q3 2006, quarterly: no employee count, 0 FTE
Arrow keys move through the periods, Home and End go to the first and the latest, Escape returns to the latest.
| Period | Q3 2006 |
|---|---|
| Employees | No count |
| FTE | 0 |
| Series | Quarterly |
The legal entity's headcount in CVR, not the annual report's average, which may cover a group.
Source: CVR, latest Q3 2006, published 18 Jul 2007.
The company's own figures, in DKK, from the annual reports filed in XBRL.
2025, DKK: Gross profit -116K, Result for the year -377.2K
Arrow keys move through the years, Home and End go to the first and the latest, Escape returns to the latest.
2025, DKK: Total assets 449.2K, Equity -2.7M
Arrow keys move through the years, Home and End go to the first and the latest, Escape returns to the latest.
| DKK thousands | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Gross profit | -224 | -205 | -150 | -85 | -116 |
| Result for the year | -273 | -249 | -355 | -309 | -377 |
| Equity | -1,419 | -1,668 | -2,022 | -2,331 | -2,708 |
| Total assets | 487 | 477 | 434 | 437 | 449 |
| Employees (average) | Not reported | Not reported | Not reported | Not reported | 0 |
| Credit metrics (Dandex calculations) | |||||
| EBITDA / gross profit (EBITDA i procent af bruttofortjenesten)Pro: EBITDA / gross profit (EBITDA i procent af bruttofortjenesten) is in the Pro plan, see pricingEBITDA as a share of gross profit. | Pro: EBITDA / gross profit (EBITDA i procent af bruttofortjenesten) is in the Pro plan, see pricingEBITDA as a share of gross profit. | ||||
| Net interest-bearing debt (NIBD, nettorentebærende gæld)Pro: Net interest-bearing debt (NIBD, nettorentebærende gæld) is in the Pro plan, see pricingInterest-bearing debt less cash and current securities; negative is net cash. | Pro: Net interest-bearing debt (NIBD, nettorentebærende gæld) is in the Pro plan, see pricingInterest-bearing debt less cash and current securities; negative is net cash. | ||||
| Gearing, NIBD / EBITDAPro: Gearing, NIBD / EBITDA is in the Pro plan, see pricingNet interest-bearing debt over EBITDA: the years of earnings the debt takes. | Pro: Gearing, NIBD / EBITDA is in the Pro plan, see pricingNet interest-bearing debt over EBITDA: the years of earnings the debt takes. | ||||
| Interest coverage (rentedækning)Pro: Interest coverage (rentedækning) is in the Pro plan, see pricingEBIT over finance expenses: how many times earnings cover the interest. | Pro: Interest coverage (rentedækning) is in the Pro plan, see pricingEBIT over finance expenses: how many times earnings cover the interest. | ||||
| Adjusted equity ratio (justeret soliditetsgrad)Pro: Adjusted equity ratio (justeret soliditetsgrad) is in the Pro plan, see pricingAdjusted equity as a share of total assets on the same basis. | Pro: Adjusted equity ratio (justeret soliditetsgrad) is in the Pro plan, see pricingAdjusted equity as a share of total assets on the same basis. | ||||
| ROIC (afkast af investeret kapital)Pro: ROIC (afkast af investeret kapital) is in the Pro plan, see pricingReturn on invested capital: EBIT after tax over equity plus net debt. | Pro: ROIC (afkast af investeret kapital) is in the Pro plan, see pricingReturn on invested capital: EBIT after tax over equity plus net debt. | ||||
| Capex % of sales (investeringer i procent af omsætningen)Pro: Capex % of sales (investeringer i procent af omsætningen) is in the Pro plan, see pricingCapex as a share of revenue. | Pro: Capex % of sales (investeringer i procent af omsætningen) is in the Pro plan, see pricingCapex as a share of revenue. | ||||
| FCFF / EBITDA (pengestrømskonvertering)Pro: FCFF / EBITDA (pengestrømskonvertering) is in the Pro plan, see pricingFree cash flow to the firm as a share of EBITDA. | Pro: FCFF / EBITDA (pengestrømskonvertering) is in the Pro plan, see pricingFree cash flow to the firm as a share of EBITDA. | ||||
Credit metrics are Dandex calculations, not filed values; grey figures are estimates with a note. Definitions. Revenue-based rows are empty: the company reports gross profit only (bruttofortjeneste), which class B filers may.
Pro: Signals (signaler) are in the Pro plan, see pricingChanges worth a look, raised from the registry and new annual reports.
New leadership (nyt lederskab), New company (ny virksomhed), Ownership change (ejerskifte), Relocation (flytning), Growth surge (vækstspurt), Headcount decline (nedgang i ansatte), Restructuring (omstrukturering), Industry change (brancheskift), Board change (bestyrelsesændring), Dissolution (ophør), Distress warning (risikoadvarsel), Fund investment (fondsinvestering), Fund exit (fondsexit), Fund board seat (fondsbestyrelsespost).
What Pro holds for ZADEC ApS:
Have Pro? Sign in.
Amounts in DKK.
| Date | Change | Cash price | Paid in | Implied value | Capital after |
|---|---|---|---|---|---|
| IncreaseMergerPaid in 2,724,666 | None | 2,724,666 | None | 500,021 | |
| IncreaseDebt conversionPaid in 127,593,285 | None | 127,593,285 | None | 500,001 | |
| FoundingNot read from the announcement | None | None | None | 500,000 |
Source: Erhvervsstyrelsen's announcements, shown where the amounts add up to the registered capital.
Merger (fusion), as the continuing company (fortsættende selskab)
Merger (fusion), as the continuing company (fortsættende selskab)
Source: CVR, read 17 Nov 2026.
Counts include corrections, and an audit firm that re-registered under a new entity.
Source: CVR, read 17 Nov 2026.
17 registrations, as published by Erhvervsstyrelsen. People's street addresses are cut to postcode and city.
Revision:
Fratrådte:
DELOITTE STATSAUTORISERET REVISIONSPARTNERSELSKAB, den 01.09.2026.
Tiltrådte:
CVR-NR. 37543128 Cedra Godkendt Revisionsaktieselskab, Sønderbrogade 16, 8700 Horsens, den 01.09.2026.
Ny adresse: c/o MC2 Therapeutics A/S, Agern Alle 24-26, 2970 Hørsholm
Erhvervsstyrelsen har modtaget oplysning om, at der er truffet beslutning om nedenstående fusion. Kapitalejerne har i enighed besluttet, at der ikke skal udarbejdes en fusionsplan. Der er endvidere modtaget erklæring fra vurderingsmændene om, at kreditorerne i de deltagende selskaber må antages at være tilstrækkeligt sikrede efter fusionen.
Virksomheden er fusioneret med CVR-nummer: 29600937 DRUGMODE ApS, der samtidigt er opløst.
Vedtægter ændret: 21.12.2015
Nye binavne: DrugMode ApS, DrugMap ApS, Pride Proteomics ApS
Kapitalforhøjelse: kr. 20,00, indbetalt ved fusion, kurs 13.623.330,00.
Kapitalen udgør herefter kr. 500.021,00.
Vedtægter ændret: 18.12.2015
Kapitalforhøjelse: kr. 1,00, indbetalt ved konvertering af gæld, kurs 12.759.328.504,00.
Kapitalen udgør herefter kr. 500.001,00.
CVR-nummer
29312206.
NAVN:
ZADEC ApS.
Adresse: c/o MC2 Biotek ApS, Bøge Alle 5, 2970 Hørsholm.
Kommune: Rudersdal.
Ny adresse: Agern Alle 24-26, 2970 Hørsholm
Ny kommune: Rudersdal
Vedtægter ændret:
06.07.2011.
Nyt binavn: ZADEC HOLDING ApS.
Selskabet er fusioneret med CVR-NR. 29426791 ZADEC HOLDING ApS, der samtidig er opløst.
Vedtægter ændret:
27.05.2010.
Ny adresse:
c/o MC2 Biotek ApS, Bøge Alle 5, 2970 Hørsholm.
Ny kommune:
Rudersdal.
Ny adresse:
c/o MC2 Biotek ApS, Tuborg Havnevej 19, 2900 Hellerup.
Direktion:
Udtrådt af direktionen:
Anette Merete Nøhr Clausen, den 30.11.2006.
Indtrådt i direktionen:
Advokat Jesper Jørn Lange, den 30.11.2006.
Ny adresse:
c/o MC2 Biotek ApS, Tuborg Havnevej 18, 2900 Hellerup.
Vedtægter ændret:
06.10.2006.
Regnskabsår ændret til:
01.01 - 31.12.
Første regnskabsår:
23.01.2006 - 31.12.2006.
Direktion:
Udtrådt af direktionen:
Steen Sindet-Pedersen, den 19.09.2006.
Indtrådt i direktionen:
Direktør Anette Merete Nøhr Clausen, den 19.09.2006.
Stiftelsesdato:
23.01.2006.
Seneste vedtægtsdato:
23.01.2006.
Kapital:
kr. 500.000,00.
Indbetalingsmåde:
kontant kr. 500.000,00 til kurs 700,00.
Stifter:
Advokat Jesper Jørn Lange, den 23.01.2006.
Direktion:
Steen Sindet-Pedersen, den 23.01.2006.
Selskabet tegnes af direktøren.
Revision:
CVR-NR. 24213714 DELOITTE STATSAUTORISERET REVISIONSAKTIESELSKAB, Weidekampsgade 6, 2300 København S, den 23.01.2006.
Første regnskabsår:
23.01.2006 - 30.06.2007.
Regnskabsår:
01.07 - 30.06.
P-number 1011992516Agern Alle 24, 2970 Hørsholm